BridgeBio Pharma, Inc.

US$74.29As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:BBIOHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR 14.76%
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.94
PE TTM —
TSR TTM 18.60%
Mkt cap US$14.47B
ROIC (17.67%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$85
14.77%
(87.98%)
Hold 3|9|10|6|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.24
1.19
1.15
1.10
20.49%
10.93%
(3.97%)
(8.92%)
Revenue$B
1.285
1.321
1.378
1.424
11.70%
10.01%
14.21%
11.85%
Peers (US$14.47B)
Cap (US$)
PE
16.98B
20.78x
Capital
TTM
5Y
10Y
Leveragex
1.332
0.436
0.354
EBIT/Intx
0.588
0.501
0.501
Own earn%
117.16
94.45
77.06
Sh yield%
23.61
21.35
23.22
Owners
Insiders/Inst%
4.83
77.83
Short interest%
4.43
SBC / revenue%
2.01
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
11–14
$1 testx
—
Incr. ROIC%
−1